Glitaray M 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and increases peripheral insulin sensitivity, contributing to better glucose uptake and utilization. This dual-action formulation offers complementary mechanisms to effectively reduce blood glucose levels in patients inadequately controlled by diet and exercise alone. Glitaray M 1 Tablet PR is typically prescribed when monotherapy with either agent is insufficient, providing improved efficacy in glycemic management. It is essential to use this medication under medical supervision, considering contraindications such as renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects like hypoglycemia and gastrointestinal disturbances is recommended. Dose adjustments may be necessary based on therapeutic response and tolerability. Glitaray M 1 Tablet PR should be used as part of a comprehensive diabetes management plan, including diet modification and physical activity, to optimize patient outcomes and minimize complications associated with type 2 diabetes mellitus.